| Identification | Back Directory | [Name]
Romifidine | [CAS]
65896-16-4 | [Synonyms]
Romidys
St 2130
STH 2130
Romifidine
Romifidinum
Romifidine >
2-(2-Bromo-6-fluoroanilino)-2-imidazoline
2-(2-Bromo-6-fluorophenylamino)-2-imidazoline
N-(2-Bromo-6-fluorophenyl)-4,5-dihydro-1H-imidazol-2-amine
1H-Imidazol-2-amine, N-(2-bromo-6-fluorophenyl)-4,5-dihydro- | [Molecular Formula]
C9H9BrFN3 | [MDL Number]
MFCD00868606 | [MOL File]
65896-16-4.mol | [Molecular Weight]
258.093 |
| Chemical Properties | Back Directory | [Melting point ]
110 °C | [Boiling point ]
303.2±52.0 °C(Predicted) | [density ]
1.72±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 250 mg/mL (968.65 mM; Need ultrasonic) | [form ]
powder to crystal | [pka]
8.69±0.50(Predicted) | [color ]
White to Light yellow |
| Hazard Information | Back Directory | [Uses]
Romifidine is an α2 adrenergic receptor agonist. Romifidine shows sedation effects in vivo[1][2]. | [in vivo]
Romifidine (80 μg/kg; i.v. once) produces sedative effects with significantly greater drooping during the 45-90 min time period in welsh mountain ponies[1].
Romifidine (40, 80 and 120 mg/kg; i.v. at seven-day intervals) shows a shallower and shorter-lived sedation than with detomidine in horses[2]. | [storage]
Store at -20°C | [References]
[1] England GC, et al. A comparison of the sedative effects of three alpha 2-adrenoceptor agonists (romifidine, detomidine and xylazine) in the horse. J Vet Pharmacol Ther. 1992 Jun;15(2):194-201. DOI:10.1111/j.1365-2885.1992.tb01007.x
[2] Hamm D, et al. Sedative and analgesic effects of detomidine and romifidine in horses. Vet Rec. 1995 Apr 1;136(13):324-7. DOI:10.1136/vr.136.13.324 |
|
|